Retatrutide

What Is Retatrutide?

This investigational triple hormone receptor agonist is being studied for obesity and metabolic health. If you are researching where to buy Retatrutide Europe, understanding the peptide’s clinical development and regulatory status is an important first step. In contrast Semaglutide, which targets the GLP-1 (glucagon-like peptide-1) receptor, and Tirzepatide, which targets GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, Retatrutide acts on three pathways: GLP-1, GIP, and glucagon.

Each receptor is associated with a different metabolic pathway. GLP-1 and GIP have been linked to the control of appetite, whereas activation of the glucagon receptors is being studied for its role in energy expenditure (the energy your body uses throughout the day).

In one of the Phase 2 studies reported in The New England Journal of Medicine (Jastreboff et al., 2023), subjects who were administered the highest dosage (12 mg) recorded a mean body weight loss of 24.2% after 48 weeks.

The Triple-Agonist Mechanism Explained

Many of the Retatrutide benefits being studied are linked to its ability to activate three hormone receptors involved in metabolic regulation:

• GLP-1. Effects include suppressing appetite, delaying gastric emptying (how fast food moves out of the stomach), and improved glycaemic control (blood sugar regulation). It is similar to how Semaglutide and Tirzepatide work.
• GIP. Characterized by the increased ability of the body to metabolize fats within the adipose tissues, better nutrient distribution, and increased action of GLP-1 on hunger regulation. The receptor is also a target for Tirzepatide.
• Glucagon. This feature distinguishes Retatrutide from GLP-1 and dual-agonist therapies. Activation of glucagon receptors is linked to fat oxidation in the liver (fat utilization by the liver as an energy source), increased resting energy expenditure (the energy burnt at rest), and lipolysis (fat breakdown for energy purposes).

Phase 2 Clinical Results

As has been mentioned earlier, patients who received the largest dosage, 12 mg, experienced a weight reduction of 24.2% at week 48 during Phase 2 of the clinical study. Researchers also noted that weight loss had not plateaued by that point, indicating that maximum efficacy had likely not yet been realized during the course of this study.

For example, a reduction of 24.2% of one’s body weight would equate to a reduction of 24 kg in a 100-kg individual. Research is ongoing on the effects that Retatrutide’s triple-agonism can have on body composition, energy consumption, and long-term metabolic outcomes.

These findings established Retatrutide as one of the most closely watched investigational weight loss peptides in clinical development with additional Phase 3 studies ongoing.

Who Is Retatrutide Best For?

Retatrutide is being studied in adults with obesity and overweight across multiple Phase 3 trials. Research includes obesity, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, knee osteoarthritis, and metabolic dysfunction-associated steatotic liver disease (MASLD).

If you are researching Retatrutide dosage, it is important to note that dosing protocols used in clinical trials involve gradual dose escalation to help participants adapt to treatment over time.

Suggested further reading:

• TRIUMPH-1 Phase 3 obesity trial (weight management);
• TRIUMPH cardiovascular outcomes study (obesity, cardiovascular disease, and kidney outcomes);
• Phase 3 study in severe obesity and established cardiovascular disease;
• Overview of the TRIUMPH clinical development program.